{"filing":{"accession_number":"0001193125-26-375495","cik":"0001503802","ticker":"KPTI","company_name":"Karyopharm Therapeutics Inc.","form":"8-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"d423030d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526375495/d423030d8k.htm"},"events":[{"id":30508,"run_id":27958,"accession_number":"0001193125-26-375495","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Karyopharm announced submission of a supplemental New Drug Application (sNDA) to the FDA seeking Accelerated Approval for XPOVIO in combination with ruxolitinib for myelofibrosis, with a request for Priority Review. This is a material regulatory and operational milestone in the drug development and commercialization process that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects. While the filing does not fit neatly into predefined categories like earnings, M\u0026A, or litigation, it represents a significant operational/strategic development in the company's core business of bringing therapeutics to market.","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-08-31","form":"8-K","submitted_at":null,"items":[{"id":33122,"accession_number":"0001193125-26-375495","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Karyopharm announced submission of a supplemental New Drug Application (sNDA) to the FDA seeking Accelerated Approval for XPOVIO in combination with ruxolitinib for myelofibrosis, with a request for Priority Review. This is a material regulatory and operational milestone in the drug development and commercialization process that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects. While the filing does not fit neatly into predefined categories like earnings, M\u0026A, or litigation, it represents a significant operational/strategic development in the company's core business of bringing therapeutics to market.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T12:10:02.164350+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33122,"accession_number":"0001193125-26-375495","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Karyopharm announced submission of a supplemental New Drug Application (sNDA) to the FDA seeking Accelerated Approval for XPOVIO in combination with ruxolitinib for myelofibrosis, with a request for Priority Review. This is a material regulatory and operational milestone in the drug development and commercialization process that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects. While the filing does not fit neatly into predefined categories like earnings, M\u0026A, or litigation, it represents a significant operational/strategic development in the company's core business of bringing therapeutics to market.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T12:10:02.164350+00:00","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-08-31"}]}